

Dapsone Imine Derivatives

Subjects: **Chemistry, Medicinal**

Contributor: Virginia Flores-Morales

Dapsone (DDS) is an antibacterial drug with well-known antioxidant properties. However, the antioxidant behavior of its derivatives has not been well explored. In the present work, the antioxidant activity of 10 dapsone derivatives 4-substituted was determined by an evaluation in two *in vitro* models (DPPH radical scavenging assay and ferric reducing antioxidant power). These imine derivatives 1–10 were obtained through condensation between DDS and the corresponding aromatic aldehydes 4-substituted. Three derivatives presented better results than DDS in the determination of DPPH (2, 9, and 10). Likewise, we have three compounds with better reducing activity than dapsone (4, 9, and 10). In order to be more insight, the redox process, a conceptual DFT analysis was carried out. Molecular descriptors such as electronic distribution, the total charge accepting/donating capacity (I/A), and the partial charge accepting/donating capacity (ω^+/ω^-) were calculated to analyze the relative donor-acceptor capacity through employing a donor acceptor map (DAM). The DFT calculation allowed us to establish a relationship between GAPHOMO-LUMO and DAM with the observed antioxidant effects. According to the results, we concluded that compounds 2 and 3 have the lowest R_a values, representing a good antioxidant behavior observed experimentally in DPPH radical capturing. On the other hand, derivatives 4, 9, and 10 display the best reducing capacity activity with the highest ω^- and R_d values. Consequently, we propose these compounds as the best antireductants in our DDS imine derivative series.

dapsone imines

dapsone-derivatives

antioxidant *in vitro*

1. Introduction

Dapsone (4,4'-diaminodiphenylsulfone, DDS) is an aniline derivative that belongs to the sulfone drug class. It is mainly used for leprosy treatment in combination with rifampicin and clofazimine [1][2]. Additionally, DDS has shown a prophylactic effect against *T. gondii* and *P. jiroveci* on clinical trials with HIV patients [3][4]. Furthermore, an antiparasitic effect against *P. falciparum* has been reported with DDS in combination with chlorproguanil [5]. Once absorbed, DDS is metabolized into monoacetyldapsone and *N*-hydroxyldapsone [6], being the one oxidation product responsible for the methemoglobinemia [7][8][9].

Moreover, DDS possesses an anti-inflammatory effect similar to other non-steroidal anti-inflammatory drugs [10]. It is a consequence of scavenging for oxidizing species, such as superoxide dismutase, peroxidase, and compounds such as β -carotene [11]. This activity has been explored in neuroscience research, where DDS diminishes the damage caused by oxidative stress in murine models [12].

The antioxidant properties of DDS have been explored as a corrosion inhibitor on steel imbibed on the acid medium (HCl 1 M and H₂SO₄ 0.5 M), showing an anticorrosive activity > 90% at DDS 400 ppm [13]. DDS imine derivatives with salicylaldehyde [14], indol-3-carboxaldehyde, thiophene-2-carboxaldehyde [15], and benzaldehyde [16] have shown the anticorrosive effect at the same level as the parent drug.

A structural modification strategy for drugs containing the amine functionality consists of derivatizing into amides or imines. The imine group has the advantage, from the synthetic point, of being easily accessible, which can improve the solubility and biological activity compared to the precursor amines [17][18]. Derivatization also positively impacts DDS solubility (0.16 mg/mL) when it reacts with aliphatic amino acids to reach aqueous solubilities higher than 25 mg/mL [19]. Additionally, the derivatives reported by Wadher et al., five derivatives of 4-substituted DDS imines maintain their antibacterial and antifungal activity against *E. coli*, *S. aureus*, *A. niger*, and *C. albicans* [20]. In recent years, the use of computational methods has increased considerably since they allow us to understand and explain various structural and electronic properties of molecules and correlate them with experimental data [21]. The calculation of quantum molecular descriptors is a useful tool in the study of chemical structures with antioxidant activity. The highest occupied molecular orbital (HOMO), lowest unoccupied molecular orbital (LUMO), the ionization potential (I), and electronic affinity (A) are helpful to understand the molecular stability linked with the ability to accept or donate electrons [22][23][24]. The energy values of HOMO, LUMO, and I have also been associated with the amine groups' reactivity and toxicity of DDS. Therefore, the amine group is the highest nucleophilic site and susceptible to oxidization [25]. These parameters will allow the generation of the donor-acceptor map (DAM), a useful tool to categorize any potential antioxidant substance as an electron donor or acceptor that permits us to better understand the possible antioxidant mechanism [26].

This work aims to: (i) Obtain new aromatic imine derivatives of DDS with aromatic aldehydes substituted in position 4, in order to evaluate their in vitro antioxidant activity through a chemical method using two experimental methodologies; and (ii) establish their correlation with electronic descriptors of DFT calculations.

The selection of 4-substituted derivatives in this research project was based on literature reports where the antimicrobial and antioxidant activity of imine-type derivatives have a greater effect if the substituents occupy that position [27][28]. Furthermore, our study was directed in a complementary way to evaluate the influence of the type of electron-withdrawing/electron-attracting substituents in that position in DDS derivatives.

2. Development and Findings

We prepared and characterized a DDS imine derivative series to assess their antioxidant potential compared to the parental drug. This compound series was evaluated by two in vitro models: (i) DPPH radical capturing; and (ii) ferric reducing antioxidant power. Our experimental findings were complemented with the DFT analysis in terms of (i) electronic distribution; (ii) the total charge accepting/donating capacity (I/A); (iii) the partial charge accepting/donating capacity (ω^+/ω^-); and (iv) an analysis of the relative donor-acceptor capacity through the DAM.

From the DPPH model, we found three trends: (a) Derivatives with null or lower activity than DDS, this set of derivatives have electron withdrawal groups (halogen **5–7**, cya-no **8**, and hydrogen **1**); (b) derivatives with an equivalent activity to DDS, hydroxy **2**, and cinnamyl **10**; and (c) derivatives with higher activity than DDS, specifically derivative **9** containing a carboxyl group. Therefore, the following tendency is observed carboxyl >> hydroxyl > cinnamyl > methoxy. Additionally, the reducing antioxidant/power showed a similar tendency, with the derivatives being minor or of similar activity to DDS that contain electron withdrawal groups. Moreover, the higher reducing power derivatives are carboxyl > nitro > cinnamyl > methoxy.

The antioxidant phenomena observed can be explained by an electronic behavior analysis. For derivatives **2**, **3**, and **10**, the substituents act as electron donators (good antiradical agents) due to the induction or hyperconjugation that makes it capable of stabilizing the cation-radical species formed in the electron-donating process towards DPPH or Fe^{3+} (Figure 1). Derivative **9** is also capable of stabilizing the cation-radical due to the electronic resonance on the carboxyl group. In the case of **4**, the resonance by the nitro group explains its effectiveness in the reducing power model. On the contrary, those derivatives with electron-withdrawing groups (F, Cl, Br, CN) decrease the electronic transfer availability to DPPH radical. Consequently, a null or minor activity with respect to DDS is observed.




Figure 1. Possible resonant structures of derivatives (a) **2**, (b) **4**, (c) **9**, and (d) **10**.

The calculation of molecular electronic parameters is relevant to predict the reactivity in several chemical reactions. The frontier molecular orbitals (HOMO and LUMO) are two crucial descriptors since they represent the electron-donating and electron-withdrawing capacities of a given molecule. Comparing the HOMO values of DDS and its derivatives (Table 1), we observed that all of the compounds presented lower values than DDS. Among the derivative series, **2**, **3**, and **10** have higher HOMO values that can be understood as a greater facility towards the electron donation, explaining the suitable antioxidant activities observed *in vitro*. On the other hand, according to

the $\text{Gap}_{\text{HOMO-LUMO}}$, derivatives **4**, **8**, and **10** have smaller values that involve a higher reactivity correlated to the antioxidant behavior in reducing the power assay (**Table 2**).

Table 1. HOMO, LUMO, and $\text{Gap}_{\text{HOMO-LUMO}}$ energy values.

Derivative	HOMO (eV)	LUMO (eV)	$\text{Gap}_{\text{HOMO-LUMO}}$ (eV)
1	-7.82	-0.99	6.83
2	-7.42	-0.69	6.72
3	-7.37	-1.93	6.70
4	-8.33	-2.03	6.31
5	-7.52	-0.89	6.63
6	-7.96	-1.23	6.73
7	-7.54	-1.05	6.49
8	-7.66	-1.57	6.09
9	-8.05	-1.50	6.55
10	-7.43	-1.15	6.28
DDS	-7.25	-0.30	6.95
BHT	-7.17	1.23	8.40
AA	-8.22	0.42	8.64

Table 2. Percentage of the reducing effect and correlation with DDS and ascorbic acid.

Compound	Substituent	%Reduction	Ratio Derivative/DDS	Ratio Derivative/AA
1	Hydrogen	15.0 ± 0.7 **	0.9	0.15
2	4-hydroxyl	16.9 ± 1.3 ns	1.0	0.17
3	4-methoxy	28.4 ± 0.8 ***	1.6	0.28
4	4-nitro	40.7 ± 0.2 ***	2.4	0.41
5	4-fluoro	13.2 ± 0.3 ***	0.8	0.13
6	4-chloro	14.5 ± 0.4 ***	0.8	0.15
7	4-bromo	19.3 ± 1.4 **	1.1	0.19

Compound	Substituent	%Reduction	Ratio Derivative/DDS	Ratio Derivative/AA
8	4-cyano	20.0 ± 0.8 ***	1.2	0.20
9	4-carboxyl	44.8 ± 0.7 ***	2.6	0.45
10	2-phenylethylen	39.6 ± 0.1 ***	2.3	0.40
DDS		17.3 ± 0.6	1.0	0.17
AA		100.0 ± 0.3	5.8	1.00

* Significative ($p < 0.05$); ** ($p < 0.01$); *** ($p < 0.001$); ^{ns}: Non significative. Note: All of the data are expressed as average ± SD in triplicate as independent experiments.

Derivatives **3**, **4**, and **10** have a homogeneous HOMO distribution along with their molecular structure, while **9** showed the distribution mainly over the aromatic rings of DDS moiety. On the other hand, the LUMO distribution is predominantly localized in the aromatic rings linked by the imine group, this behavior is notable for derivative **4**. These observations led us to propose different scenarios where an unbalanced distribution of orbitals is required to produce the antioxidant effect (Figure 2).




Figure 2. HOMO distribution for the most active derivatives (a) methoxy **3**, (b) cinnamoyl **10**, (c) nitro **4**, and (d) carboxyl **9**.

The low I values represent compounds that are easily oxidizable and act as efficient antiradical agents depending on their specific electro-donative capacity. For example, in Table 3, we found that derivatives **2**, **3**, **5**, and **10** have the lowest I value that can be understood as a higher ease to transfer one electron and, therefore have better antiradical activity. In opposition, derivatives **1**, **4**, **6**, and **9** have the highest I value in the series, explaining the low DPPH radical capturing activity of these compounds, except for compound **9**.

Table 3. Molecular descriptors calculated for DDS and its derivatives at a CAM-B3LYP theory level and 6-311G (d,p) basis set. Values in eV.

Compound	I	A	ω^-	ω^+	R_a	R_d
1	8.14	0.64	5.24	0.84	0.37	1.53
2	7.84	0.33	4.73	0.65	0.28	1.38
3	7.77	0.33	4.69	0.64	0.28	1.37
4	8.63	1.65	6.79	1.65	0.71	1.98
5	7.98	0.51	5.00	0.75	0.33	1.46
6	8.27	0.90	5.60	1.02	0.44	1.63
7	8.00	0.71	5.24	0.88	0.38	1.53
8	8.14	1.17	5.87	1.22	0.53	1.71
9	8.35	1.16	5.97	1.21	0.53	1.74
10	7.83	0.80	5.24	0.93	0.40	1.53
DDS	7.78	-1.10	3.48	0.14	0.06	1.01
BHT	7.63	-1.64	3.04	0.05	0.02	0.89
AA	9.06	-1.16	4.14	0.19	0.08	1.21
F	21.26	1.84	13.86	2.31	1.00	4.04
Na	5.38	0.40	3.43	0.54	0.23	1.00

The results for A showed that all of the derivatives have positive values, while the DDS value is negative. The positive values indicate that the anionic structure is more stable than its corresponding neutral form. Therefore, they have a greater capacity for accepting electrons than DDS. Consequently, DDS is a less efficient antireductant. Among the derivatives, the most effective ones as antireductants are **4** > **8** > **9**, and the lowest effective ones are **3** < **2** < **5**. This interpretation of A allows us to explain that derivative **9** showed the highest activities in the DPPH radical capturing assay, based on a reaction mechanism that involves the interaction of our compound with the radical species, the electron capture, and stabilization through electronic delocalization.

Highly effective electron donors have lower values of electron-donating capacity (ω). All of the derivatives have higher values than DDS, particularly, derivatives **2**, **3**, and **5** have the lowest values within the series. With respect to the I values, it is expected that a low I value implies a tendency towards electronic transfer/donation. However, the I value for our derivatives, particularly, derivatives **4**, **6**, and **9** are higher than DDS. Consequently, a reactivity

trend referring to ω^- is proposed, as follows: BHT < DDS < AA < **3** < **2** < **5** < **1** < **7** < **10** < **6** < **8** < **9** < **4**. For the electro-accepting capacity (ω^+), high values are related to an effective electronic acceptor species. In our study, the trend for ω^+ is the following: BHT < DDS < AA < **3** < **2** < **5** < **1** < **7** < **10** < **6** < **9** < **8** < **4**. We observed here a DDS as the lowest electron acceptor in the trend above. This result correlates with the A values where the DDS has a negative value, indicating an antioxidant behavior (good electron donator). The highest ω^+ values were obtained for the derivative series for **4**, **8**, and **9** (good antireductant activity), and their experimental activity was corroborated in ferric reducing the antioxidant test. On the other hand, derivative **3** has the lowest ω^+ and showed an antioxidant activity in the ferric reducing antioxidant test.

The DAM allows us to classify substances based on their electron-donating or accepting capacity [26][29]. This work showed that DDS is positioned below BHT and AA (Figure 2). Therefore, DDS has a lower antioxidant activity than the control compound BHT. Furthermore, all of the derivatives have R_a and R_d values higher than DDS. Therefore, the full derivative series has a poor electron-donating capacity, but a good electron-accepting capacity with respect to DDS.




Figure 2. DAM for DDS derivatives **1–10**. The break is intended to visualize DDS in the DAM.

We found that derivatives **2** and **3** have the lowest R_a values representing a good antioxidant behavior that is observed experimentally in DPPH radical capturing. However, **9** has an outstanding experimental result, followed by **2**, **3**, and **10**. Regarding R_d , derivatives **4** and **9** have the highest values, and thus they classify as the compound with the better electron-withdrawing capacity into the derivative series. Furthermore, derivatives **4** and **9** display the best-reducing capacity activity in addition to the highest ω^+ and R_d . Consequently, we propose these as the best antireductants in our DDS imine derivative series.

3. Conclusions

In the present work, the antioxidant activity of 10 dapsone derivatives was evaluated by two in vitro models (DPPH radical scavenging assay and ferric reducing antioxidant power). To explain our experimental data, DFT calculations were performed and the relative donor-acceptor capacity was analyzed through the DAM. The derivatives that showed the best results, according to their antioxidant activity in both in vitro and in silico tests, were **2**, **3**, **4**, **9**, and **10**. The potential use of these derivatives as anticancer agents was evaluated in silico, considering that one of the conditions for the development of this pathology is the oxidative stress generated by free radicals. All of the derivatives showed a potential activity as anticancer agents, particularly **1**, **4**, and **6** presented $Pa > 0.5$ values related to colon carcinoma. According to the toxicity analysis, all our DDS derivatives showed low values in accordance with the EPA and GHS categories. Due to the results found in this work, in the future our derivatives, particularly **4** and **9**, may have applications in the medical area as potential therapeutic agents, specifically in processes where oxidative stress is involved.

References

1. World Health Organization. Leprosy. Available online: <https://www.who.int/news-room/fact-sheets/detail/leprosy> (accessed on 29 January 2020).
2. Fischer, M. Leprosy—an overview of clinical features, diagnosis, and treatment. *J. Dtsch. Dermatol. Ges.* **2017**, *15*, 801–827.
3. Derouin, F.; Piketty, C.; Chastang, C.; Chau, F.; Rouveix, B.; Pocidalo, J.J. Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. *Antimicrob. Agents Chemother.* **1991**, *35*, 252–255.
4. Girard, P.M.; Landman, R.; Gaudebout, C.; Olivares, R.; Saimot, A.G.; Jelazko, P.; Lecompte, T. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against *Pneumocystis carinii* pneumonia and toxoplasmosis in HIV infection. *N. Engl. J. Med.* **1993**, *328*, 1514–1520.
5. Watkins, W.M.; Brandling-Bennett, A.D.; Nevill, C.G.; Carter, J.Y.; Boriga, D.A.; Howells, R.E.; Koech, D.K. Chlorproguanil/dapsone for the treatment of non-severe *Plasmodium falciparum* malaria in Kenya: A pilot study. *Trans. R. Soc. Trop. Med. Hyg.* **1988**, *82*, 398–403.
6. Zuidema, J.; Hilbers-Modderman, E.S.M.; Merkus, F.W.H.M. Clinical pharmacokinetics of dapsone. *Clin. Pharmacokinet.* **1986**, *11*, 299–315.
7. Reilly, T.P.; Woster, P.M.; Svensson, C.K. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions. *J. Pharmacol. Exp. Ther.* **1999**, *288*, 951–959.

8. Tingle, M.D.; Mahmud, R.; Maggs, J.L.; Pirmohamed, M.; Park, B.K. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. *J. Pharmacol. Exp. Ther.* 1997, 283, 817–823.
9. Coleman, M.D. Dapsone: Modes of action, toxicity and possible strategies for increasing patient tolerance. *Brit. J. Dermatol.* 1993, 129, 507–513.
10. Wozel, G.; Blasum, C. Dapsone in dermatology and beyond. *Arch. Dermatol. Res.* 2014, 306, 103–124.
11. Niwa, Y.; Sakane, T.; Miyachi, Y. Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates—in comparision with that of colchicine and various scavengers. *Biochem. Pharmacol.* 1984, 33, 2355–2360.
12. Diaz-Ruiz, A.; Zavala, C.; Montes, S.; Ortiz-Plata, A.; Salgado-Ceballos, H.; Orozco-Suarez, S.; Nava-Ruiz, C.; Pérez-Neri, I.; Perez-Severiano, F.; Ríos, C. Antioxidant, antiinflammatory and antiapoptotic effects of dapsone in a model of brain ischemia/reperfusion in rats. *J. Neurosci. Res.* 2008, 86, 3410–3419.
13. Singh, A.; Kumar Singh, A.; Quraishi, M.A. Dapsone: A novel corrosion inhibitor for mild steel in acid media. *Open Electrochem. J.* 2010, 2, 43–51.
14. Singh, A.; Avyaya, J.N.; Ebenso, E.E.; Quraishi, M.A. Schiff's base derived from the pharmaceutical drug Dapsone (DS) as a new and effective corrosion inhibitor for mild steel in hydrochloric acid. *Res. Chem. Intermed.* 2013, 39, 537–551.
15. Chakravarthy, M.P.; Mohana, K.N.; Kumar, C.P.; Badiea, A.M. Corrosion inhibition behaviour and adsorption characteristics of dapsone derivatives on mild steel in acid medium. *Chem. Sci. Int. J.* 2015, 8, 1–16.
16. Singh, P.; Chauhan, D.S.; Chauhan, S.S.; Singh, G.; Quraishi, M.A. Chemically modified expired dapsone drug as environmentally benign corrosion inhibitor for mild steel in sulphuric acid useful for industrial pickling process. *J. Mol. Liq.* 2019, 286, 110903.
17. Jornada, D.H.; dos Santos Fernandes, G.F.; Chiba, D.E.; De Melo, T.R.F.; Dos Santos, J.L.; Chung, M.C. The prodrug approach: A successful tool for improving drug solubility. *Molecules* 2016, 21, 42.
18. Day, T.P.; Sil, D.; Shukla, N.M.; Anbanandam, A.; Day, V.W.; David, S.A. Imbuing aqueous solubility to amphotericin B and nystatin with a vitamin. *Mol. Pharm.* 2011, 8, 297–301.
19. Pochopin, N.L.; Charman, W.N.; Stella, V.J. Amino acid derivatives of dapsone as water-soluble prodrugs. *Int. J. Pharm.* 1995, 121, 157–167.
20. Wadher, S.J.; Puranik, M.P.; Karande, N.A.; Yeole, P.G. Synthesis and biological evaluation of Schiff base of dapsone and their derivative as antimicrobial agents. *Int. J. PharmTech Res.* 2009,

1, 22–33.

21. Althagafi, I.I.; Gaffer, H.E. Synthesis, molecular modeling and antioxidant activity of new phenolic bis-azobenzene derivatives. *J. Mol. Struct.* 2019, 1182, 22–30.

22. Alaşalvar, C.; Soylu, M.S.; Güder, A.; Albayrak, Ç.; Apaydın, G.; Dilek, N. Crystal structure, DFT and HF calculations and radical scavenging activities of (E)-4, 6-dibromo-3-methoxy-2- phenol. *Spectrochim. Acta A* 2014, 125, 319–327.

23. Horton, W.; Peerannawar, S.; Török, B.; Török, M. Theoretical and experimental analysis of the antioxidant features of substituted phenol and aniline model compounds. *J. Struct. Chem.* 2019, 30, 23–35.

24. Mendes, A.P.; Schalcher, T.R.; Barros, T.G.; Almeida, E.D.; Maia, C.S.; Barros, C.A.; Monteiro, M.C.; Borges, R.S. A geometric and electronic study of dapsone. *J. Comput. Theor. Nanosci.* 2011, 8, 1428–1431.

25. Borges, R.S.; Vale, J.K.; Schalcher, T.R.; Almeida, E.D.; Maia, C.S.; Monteiro, M.C.; Orestes, E.; da Silva, A.B. A theoretical study of the dapsone derivatives on methemoglobin. *J. Comput. Theor. Nanosci.* 2013, 10, 2029–2033.

26. Martínez, A.; Rodríguez-Gironés, M.A.; Barbosa, A.; Costas, M. Donator acceptor map for carotenoids, melatonin and vitamins. *J. Phys. Chem. A* 2008, 112, 9037–9042.

27. Mermer, A.; Demirbas, N.; Uslu, H.; Demirbas, A.; Ceylan, S.; Sirin, Y. Synthesis of novel Schiff bases using green chemistry techniques; antimicrobial, antioxidant, antiurease activity screening and molecular docking studies. *J. Mol. Struct.* 2019, 1181, 412–422.

28. Paşa, S.; Erdoğan, Ö.; Yenisey, Ç. Synthesis and structural identification of boron based Schiff compounds with Ishikawa endometrial cancer and antioxidant activity. *J. Mol. Struct.* 2019, 1186, 458–467.

29. Martinez, A. Donator acceptor map of psittacofulvins and anthocyanins: Are they good antioxidant substances? *J. Phys. Chem. B* 2009, 113, 4915–4921.

Retrieved from <https://encyclopedia.pub/entry/history/show/34943>